An invention created at the University of Toledo in northwest Ohio could turn ADS Biotechnology Corp. into one of the next big medical companies, recently shared The Toledo Blade.
ADS is developing a blood volume replacement product to treat trauma patients -- a technology that was initially developed by a trio of UT researchers. The company is on track to bring the product to market in seven or eight years.
ADS Biotechnology is one of 14 companies that have sprung out of UT's technology transfer program in recent years. University officials, as well as local economic development groups, say the program is playing an instrumental role in creating the next generation of high-tech start-up companies in metro Toledo and around the country. UT has aided ADS by connecting the firm with investors and other business resources.
Ohio's bioscience leadership stimulates knowledge transfer that promotes innovation and allows quick and cost effective solutions to scientific challenges. Learn more about Ohio's bioscience industry.
With more than $2.5 billion in funding and 1,141 bioscience entities in operation throughout the state, Ohio is establishing an international leadership role in the cutting-edge bioscience industry. The state's bioscience and bioproducts Industry centers on research, development and marketing of pharmaceuticals, diagnostics, bioinformatics, bioproduct materials, manufacturing, medical devices, medical equipment, services based on biotechnology, computer systems and software for managing healthcare and other health-related products. Bioscience companies represent not only the next wave for the global economy but also opportunity for dramatic advances in the human experience.
The Ohio Third Frontier, the state's tech-based economic development initiative, has been a leader in fostering bioscience collaboration across the state. Between January 2002 and June 2008, over $400 million of $1.6 billion Ohio Third Frontier funds had been competitively awarded to support bioscience-related development and commercialization initiatives. Since 2002 more than 90 diverse biomedical projects have been funded by Ohio's Third Frontier, epitomizing the breadth and depth of the state's bioscience-based economic development.
Read more about Ohio's bioscience industry in hiVelocity's article, "Biomedical economy grows behind collaboration, partnerships."
The Center for Stem Cell and Regenerative Medicine (CSCRM) in Cleveland, Ohio is part of the Ohio-based National Center for Regenerative Medicine, which is the 4th largest stem cell research organization in the U.S. Bringing together a diverse array of experts, CSCRM provides comprehensive stem cell research aimed at delivering breakthroughs in treating a range of human diseases. CSCRM is comprised of researchers and clinicians from leading Ohio-based medical institutions: Case Western Reserve University, University Hospitals Case Medical Center, The Cleveland Clinic, Athersys Inc. and The Ohio State University.
Debra Grega, Ph.D., executive director at CSCRM, coordinates interdisciplinary research groups, biotechnology business and product development. Dr. Grega joined CSCRM in March 2004 after working for nearly 20 years in the commercial biotechnology industry working for companies such as Athersys Inc. and Roche Diagnostics/Boehringer Mannheim Corporation.
Building on the 30-year history of adult stem cell research in Northeast Ohio, CSCRM was created in 2003 with a $19.4 million award from the State of Ohio as a Wright Center of Innovation from the Ohio Third Frontier, an unprecedented and bipartisan state commitment to create technology-based products, companies, industries and jobs. In 2006, CSCRM received an $8 million award, and again in June 2009, a $5 million award from the Ohio Third Frontier’s Research and Commercialization Program.
Read Dr. Grega's full story and find out more about the Ohio Third Frontier.
Ohio offers Battelle, the world's largest non-profit independent research and development organization, renowned hospitals, research centers and manufacturing facilities working together to develop new advances in bioscience. Their location in Ohio proves that scientific discovery thrives in the heart of the Midwest, where practical innovation is hard at work.
The company’s Health and Life Sciences Global Business delivers comprehensive R&D services – solving complex challenges in the biotechnology, medical device, pharmaceutical and public health sectors. Battelle also forges alliances on related initiatives with other organizations to generate world-class research and drive award-winning clinical practice.
A $5-million federal grant is aimed at revving up the skills of Ohio's displaced auto and other workers, training them for jobs in the growing bioscience world, according to hiVelocity in an article on September 23.
The initiative will take place over three years, and more than $2.8 million of grant has been set aside for tuition reimbursement and trainee scholarships
The dollars will be used to create new programs or build on new ones at the colleges, which are partnering with employers and labor, workforce development and non-profit organizations to develop programs to retrain and identify workers in Ohio's auto and other declining industries.
The program is focused not just on education and training but moving people into jobs through the public and private partnerships says Dr. Bill Tacon, Senior Director, Workforce & Education at BioOhio.
"We will help them find a job. We're not simply training and just letting them go. Each has an industry advisory board, and when we got the grant the industry advisory board signed a letter of commitment saying they are looking at new potential hires," Tacon says.
Debra Grega, Ph.D., executive director at CSCRM, coordinates interdisciplinary research groups, biotechnology business and product development. Dr. Grega joined CSCRM in March 2004 after working for nearly 20 years in the commercial biotechnology industry working for companies such as Athersys Inc. and Roche Diagnostics/Boehringer Mannheim Corporation.